secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001654954-22-014938
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar Q3 net loss $2.4M ($0.19/share); cash $14.3M; Validive interim analysis Q1 2023
--------------------------------------------------------------------------------

- Net loss of $2.4M ($0.19 per share) vs. $2.5M ($0.20) in Q3 2021; R&D $1.73M, G&A $0.68M.
- Cash and equivalents $14.3M; expects to fund VOICE Phase 2b and camsirubicin Ph1b through Nov 2023.
- Validive VOICE trial: 73 active sites, >130 patients dosed; Phase 2b enrollment complete; Phase 3 enrollment started.
- Blinded interim analysis of Validive Phase 2b data expected to be reported in Q1 2023.
- Camsirubicin Ph1b data to be presented at CTOS Nov 16-19; MNPR-202 preclinical data at ASH Dec 10-13.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000165495422014938/0001654954-22-014938-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000165495422014938/mnpr_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-014938

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer